Sandra Albanese

National Research Council (CNR)

SCHOLARLY PAPERS

1

DOWNLOADS

56

TOTAL CITATIONS

0

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

A Novel Cd44-Targeting Aptamer Recognizes Chemoresistant Mesenchymal Stem-Like  Tnbc Cells and Inhibits Tumor Growth

Number of pages: 53 Posted: 04 Feb 2025
Alessandra Caliendo, Simona Camorani, Luis Exequiel Ibarra, Gabriella Pinto, Lisa Agnello, Sandra Albanese, Antonietta Caianiello, Anna Illiano, Rosaria Festa, Vincenzo Ambrosio, Giosuè Scognamiglio, Monica Cantile, Angela Amoresano, Monica Fedele, Antonella Zannetti and Laura Cerchia
National Research Council (CNR) - Institute of Experimental Endocrinology and Oncology "G. Salvatore" (IEOS), National Research Council (CNR) - Institute of Experimental Endocrinology and Oncology "G. Salvatore" (IEOS), Universidad Nacional de Río Cuarto, University of Naples Federico II, National Research Council (CNR) - Institute of Experimental Endocrinology and Oncology "G. Salvatore" (IEOS), National Research Council (CNR), National Research Council (CNR) - Institute of Experimental Endocrinology and Oncology "G. Salvatore" (IEOS), University of Naples Federico II, National Research Council (CNR) - Institute of Experimental Endocrinology and Oncology "G. Salvatore" (IEOS), National Research Council (CNR) - Institute of Experimental Endocrinology and Oncology "G. Salvatore" (IEOS), Government of the Italian Republic (Italy) - National Cancer Institute, Government of the Italian Republic (Italy) - National Cancer Institute, University of Naples Federico II, National Research Council (CNR) - Institute of Experimental Endocrinology and Oncology "G. Salvatore" (IEOS), National Research Council (CNR) - Institute of Experimental Endocrinology and Oncology "G. Salvatore" (IEOS) and National Research Council (CNR) - Institute of Experimental Endocrinology and Oncology "G. Salvatore" (IEOS)
Downloads 56 (808,538)

Abstract:

Loading...

aptamer, CD44, chemoresistant triple-negative breast cancer, biomarker identification, targeted cancer therapy